Pricing Log in Create free account
Saturday 17 October 2026 Export LIVN’s income statement to Excel — free account

LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — 1 1 — 2 2 —
Insider Ownership 0.18%

Capital & Financial Ratios $m

Market Cap 4,320.00
Revenue 1,471.52
Net Income 188.55
Free Cash Flow 155.59
Net Debt (223.13)
Current Ratio 1.45
Debt/Equity 0.22 (at or below 0.5: strong)
P/E ratio 22.49
Fwd P/E 26.00
P/S ratio 2.90
P/B ratio 3.22
Past 5Y EPS Growth —
This Y EPS Growth 11.71%
Next Y EPS Growth 7.51%
Next Y revenue growth 9.65%
Next 5Y EPS Growth 10.32%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.7×, against a ten-year median of 3.0×; over the ten years it ranged from 1.5× in 2025 to 5.8× in 2018.
P/S against its own 10 years 45.89%
10-year low 10-year high
P/B against its own 10 years 86.62%
10-year low 10-year high
EV/Sales against its own 10 years 37.56%
10-year low 10-year high
EV/FCF against its own 10 years 21.57%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 578 724 636 517
Receivables 215 193 216 231
Inventory 148 148 165 173
Other — — — —
988 1,127 1,102 1,025
2023 2024 2025 Q'26
Payables 81 70 97 103
ST’ Debt 18 78 31 4
Other 11 13 459 405
335 392 808 707

Compound Annual Growth %

10y 5y 3y
Sales 16.89% 8.24% 10.75%
Cash Flow 12.31% 0.00% 53.79%
Earnings 0.00% 0.00% 0.00%
Book Value (4.03%) 1.58% (0.21%)

Revenue $m

Mar Jun Sep Dec Year
’26 362 391 — — —
’25 317 353 358 361 1,388
’24 295 319 318 322 1,253
’23 263 294 286 310 1,154
’22 240 254 253 275 1,022
’21 248 264 253 270 1,035
’20 242 182 240 270 934
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 15 67 — — —
’25 24 63 85 82 254
’24 10 43 51 79 183
’23 21 (18) 18 54 75
’22 26 (10) 36 19 70
’21 19 26 24 33 103
’20 (106) (19) 9 37 (79)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 35 — — —
’25 13 48 62 57 181
’24 4 31 33 68 136
’23 13 (24) 9 42 41
’22 21 (16) 30 10 43
’21 11 19 21 26 77
’20 (114) (29) (2) 30 (114)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.40 1.93 — — —
’25 (6.01) 0.50 0.49 0.56 (4.45)
’24 (0.78) 0.30 0.60 1.02 1.16
’23 0.14 0.02 (0.14) 0.30 0.32
’22 0.06 0.30 (2.01) 0.03 (1.61)
’21 (0.61) (1.13) (0.82) (0.10) (2.68)
’20 0.77 (1.81) (0.30) (5.75) (7.10)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 40.84 44.72 79.35 64.80 33.40 61.73 41.82 40.26 43.15 32.48

Analyst estimates 2026–2028

Powerpack
High 63.21 88.56 131.54 102.43 80.75 93.89 88.00 59.86 64.48 65.57
People
People Employees 4,500 4,500 4,000 4,000 4,000 3,000 2,900 2,900 2,900 3,300
Revenue/emp, $m 0.21 0.22 0.28 0.27 0.23 0.35 0.35 0.40 0.43 0.42
Income, $m
Income, $m Revenue 965 1,012 1,107 1,084 934 1,035 1,022 1,154 1,253 1,388
Gross margin, % 57.99 64.39 66.39 66.76 63.66 68.19 69.21 65.52 68.09 67.71
EBT 26 121 (247) (188) (348) (124) (75) (81) 88 (221)
EBT margin, % 2.66 11.97 (22.35) (17.38) (37.25) (12.02) (7.35) (7.04) 7.05 (15.91)
Net income (63) (25) (189) (158) (349) (136) (86) 18 63 (242)
Depreciation 130 115 84 128 112 85 209 80 73 83
Per share, $
Per share, $ Revenue 19.75 21.02 22.83 22.42 19.23 20.45 19.11 21.39 23.11 25.45
Earnings (1.29) (0.52) (3.91) (3.21) (7.10) (2.68) (1.61) 0.33 1.17 (4.45)
Cash flow 1.85 1.90 2.48 (1.89) (1.63) 2.03 1.31 1.39 3.37 4.66
Capex (0.76) (0.58) (0.49) (0.58) (0.72) (0.50) (0.50) (0.63) (0.87) (1.35)
Free cash flow 1.08 1.31 1.99 (2.46) (2.36) 1.52 0.81 0.76 2.51 3.31
Book value 34.93 37.70 31.01 28.62 22.83 25.57 22.58 23.69 24.34 22.00
Shares, m 49 48 48 48 49 51 53 54 54 55
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 157.94 39.92 0.00
P/S 2.30 3.80 4.01 3.36 3.44 4.28 2.89 2.36 2.00 2.42
P/B 1.30 2.12 2.95 2.64 2.90 3.42 2.44 2.13 1.90 2.80
EV/Sales 2.38 3.86 4.12 3.62 3.87 4.31 2.91 2.37 1.93 2.23
EV/FCF 50.10 66.85 47.70 (32.92) (30.73) 60.48 74.33 72.48 18.21 17.48
Cash, $m
Cash, $m Operating cash flow 90 91 120 (91) (79) 103 70 75 183 254
Capex (37) (28) (24) (28) (35) (25) (27) (34) (47) (74)
Free cash flow 53 63 97 (119) (114) 77 43 41 136 181
Balance, $m
Balance, $m Working capital 463 464 37 37 399 (18) 589 653 735 294
Total debt 123 146 168 338 656 240 542 587 628 377
Net debt 83 52 121 277 403 32 26 9 (96) (259)
Shareholders’ equity 1,707 1,815 1,504 1,384 1,109 1,295 1,208 1,278 1,320 1,200
Returns, %
Returns, % ROA (2.56) (1.04) (7.50) (6.35) (14.50) (5.90) (3.84) 0.74 2.56 (9.49)
ROIC 1.17 3.23 (9.54) (6.46) (11.32) (0.04) (3.89) (3.33) 6.59 13.24
ROE (3.57) (1.42) (11.41) (10.92) (27.98) (11.30) (6.89) 1.41 4.87 (19.24)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

LivaNova PLC vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BRKR Bruker Corporation $8.6B — (loss-making) 55.7× +5.15% (above 0%: growing) n/m +28.63% (above 0%: growing) 49.61% (7.79%) Compare
HAE Haemonetics Corporation $5.5B 57.7× 18.0× +5.60% (above 0%: growing) +2.86% (above 0%: growing) +220.38% (above 0%: growing) 59.76% 16.93% Compare
LIVN LivaNova PLC $4.3B 22.5× 26.0× +10.80% (above 0%: growing) +296.00% (above 0%: growing) −26.66% (below 0%: shrinking) 70.07% 12.67%
ITGR Integer Holdings Corporation $4.3B 34.3× 27.6× −2.60% (below 0%: shrinking) −34.91% (below 0%: shrinking) +48.81% (above 0%: growing) 24.34% 7.44% Compare
IRTC iRhythm Holdings, Inc. $3.6B — (loss-making) — (loss-making) +20.08% (above 0%: growing) n/m +116.98% (above 0%: growing) 72.80% (1.13%) Compare
NEOG Neogen Corporation $2.7B — (loss-making) — (loss-making) +6.51% (above 0%: growing) n/m +135.75% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.7B 16.0× 34.1× +20.70% (above 0%: growing) −59.22% (below 0%: shrinking) −87.62% (below 0%: shrinking) 59.59% 12.50% Compare
UFPT UFP Technologies, Inc. $2.3B 31.2× 23.6× +15.07% (above 0%: growing) +20.63% (above 0%: growing) −35.77% (below 0%: shrinking) 29.27% 16.15% Compare
BFLY Butterfly Network, Inc. $2.1B — (loss-making) — (loss-making) +39.47% (above 0%: growing) n/m −113.85% (below 0%: shrinking) 71.41% (41.90%) Compare
Median of peers $3.1B 32.7× 27.6× +10.79% −16.02% +38.72% 54.60% 3.32%

All 149 Medical Devices stocks →

LivaNova PLC (LIVN) key facts

  • Concern: LivaNova PLC reported a net loss of $242.5 million, or a loss of $4.45 per share, for fiscal 2025.
  • Strength: LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
  • LivaNova PLC (LIVN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LIVN traded at $77.60, a market capitalization of $4.3 billion.
  • At that price the stock trades at 22.5× trailing-twelve-month earnings and 2.9× sales.
  • Return on equity was −19.2% and debt-to-equity 0.22.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.74 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

LivaNova PLC (LIVN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LIVN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com